Basilea Pharmaceutica AG
0QNA.L
London Stock Exchange53.77
CHF
-0.87
- -
Basilea Pharmaceutica AG
0QNA.L
(London Stock Exchange)
Recent
price
53.77
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Basilea Pharmaceutica AG is a Swiss commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative pharmaceutical products in the anti-infectives therapeutic area. The company’s main products include Cresemba (isavuconazole), an antifungal for treating invasive fungal infections, and Zevtera (ceftobiprole), a broad-spectrum antibiotic targeting bacterial infections such as Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia. Basilea also develops clinical-stage candidates such as Fosmanogepix, a broad-spectrum antifungal with intravenous and oral formulations acquired in November 2023, and ledaborbactam etzadroxil, an oral beta-lactamase inhibitor combined with ceftibuten, an oral cephalosporin antibiotic. The company focuses on hospital and specialty care markets primarily in Europe, the United States, and Asia-Pacific. In recent major developments, Basilea entered into an agreement with BARDA in 2024 to develop novel antifungals and antibacterials, receiving initial funding of up to USD 25 million and further milestone payments contingent on development progress. In the same year, Basilea acquired a preclinical antibiotics program from Spexis AG, targeting multidrug-resistant Gram-negative bacteria, including compounds, intellectual property, and know-how, with a total consideration up to CHF 2 million. Basilea also expanded its US operations with the commercial launch of Zevtera in May 2025 through its partner Innoviva Specialty Therapeutics. Cresemba’s strong sales performance in Europe and Asia-Pacific triggered milestone payments to the company in 2024 and 2025, emphasizing growth in its marketed portfolio. Founded in 2000 and headquartered in Allschwil, Switzerland, Basilea operates in one business segment focused on pharmaceutical anti-infective products. Its geographic footprint covers major markets such as Europe, the US, Asia Pacific, and China. The company aims to address unmet medical needs in severe bacterial and fungal infections through products on the market and an expanding R&D pipeline, with ongoing clinical trials and collaborations to develop innovative therapies for resistant pathogens.